Sammanfattning
Ongoing evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus strains is posing new COVID-19 diagnosis and treatment challenges. To help efforts to meet these challenges we examined data acquired from proteomic analyses of human SARS-CoV-2-infected cell lines and samples from COVID-19 patients. Initially, 129 unique peptides were identified, which were rigorously evaluated for repeats, disorders, polymorphisms, antigenicity, immunogenicity, toxicity, allergens, sequence similarity to human proteins, and contributions from other potential cross-reacting pathogenic species or the human saliva microbiome. We also screened SARS-CoV-2-infected NBHE and A549 cell lines for presence of antigenic peptides, and identified paratope peptides from crystal structures of SARS-CoV-2 antigen-antibody complexes. We then selected four antigen peptides for docking with known viral unbound T-cell receptor (TCR), class I and II peptide major histocompatibility complex (pMHC), and identified paratope sequences. We also tested the paratope binding affinity of SARS-CoV T- and B-cell peptides that had been previously experimentally validated. The resultant antigenic peptides have high potential for generating SARS-CoV-2-specific antibodies, and the paratope peptides can be directly used to develop a COVID-19 diagnostics assay. The presented genomics and proteomics-based in-silico approaches have apparent utility for identifying new diagnostic peptides that could be used to fight SARS-CoV-2.
| Originalspråk | Engelska |
|---|---|
| Artikelnummer | 725240 |
| Antal sidor | 14 |
| Tidskrift | Frontiers in Immunology |
| Volym | 12 |
| DOI | |
| Status | Publicerad - 2021 |
FN:s SDG:er
Detta resultat bidrar till följande hållbara utvecklingsmål:
-
SDG 3 – God hälsa och välbefinnande
Nyckelord
- SARS-CoV-2
- COVID-19 vaccines
- diagnostic peptides
- docking
- paratopes
- TCR
- MHC
Citera det här
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver